NEW DELHI: Indian government formed an expert committee comprising representatives from all relevant ministries and institutions to oversee the COVID-19 vaccine plan.
The committee will be overseeing the identification of the vaccine to finance the purchase to distribution and administration. At least, six vaccines are in Phase 3 or combined Phase 2-3 trials as of now.
Nations around the world are struggling to develop a suitable vaccine which is regarded as the best and the most feasible solution to stop the pandemic and its repercussions.
The committee will be led by Niti Aayog’s Dr VK Paul and co-chaired by health secretary Rajesh Bhushan. They will pick the suitable vaccine, plan the finances and find out how expensive the purchase is running into billions of dollars, and prioritise the sequence of administration.
India is currently the third-worst infection nation after the United States and Brazil.
This panel has AIIMS director Dr Randeep Guleria, representatives of the ministries of external affairs, biotechnology, information technology, the Director-General of Health Services, India’s AIDs Research Institute, the Indian Council of Medical Research, and all.
One of the major vaccine candidates includes the Oxford AstraZeneca vaccine, being made in India by the Adar Poonawalla-led Serum Institute of India.